EPO treatment has also been found to reduce renal fibrosis in a murine model of unilateral ureteral obstruction (UUO) by inhibiting TGF-β1-induced EMT [15], suggesting that inhibition of EMT by EPO administration could be a potential therapeutic strategy to inhibit or slow CKD progression. The gene discussed is TGFB1; the disease is Ureteral obstruction.